Patients with high-risk melanoma who received the immunotherapy drug Keytruda (pembrolizumab) both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Researchers at MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer, highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors. The study was published in Cancer Cell.
MD Anderson Cancer Center and Xilis formed a strategic collaboration to use Xilis’ proprietary MicroOrganoSphere technology in support of preclinical research to accelerate the development of novel cancer therapies.
Throughout Jim Allison’s early career, the field of oncology appeared to be unfazed by his T cell research. Allison’s introduction to the now-famed immune cell came in an undergraduate immunology course, where even the professor was apprehensive about Allison’s fascination with the recently discovered T cells. “I remember going to see the professor after class […]
Jennifer Wargo, professor of surgical oncology and genomic medicine at MD Anderson Cancer Center, received a 2023 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology for her contributions to the understanding of how the gut microbiome influences responses to immunotherapy and other cancer treatments.
Afami-cel (afamitresgene autoleucel; formerly ADP-A2M4), an adoptive T-cell receptor therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial led by researchers at MD Anderson Cancer Center.
Eyal Gottlieb was named vice president for research at MD Anderson Cancer Center.
The James P. Allison Institute at MD Anderson Cancer Center received a $10 million gift from the Andrew Sabin Family Foundation and Andrew “Andy” Sabin, a senior member of the MD Anderson Cancer Center Board of Visitors.
MD Anderson Cancer Center researchers used both clinical samples and laboratory models to demonstrate that higher levels of a specific mucin-degrading bacteria are associated with a higher incidence of febrile neutropenia and that treatment with antibiotics helped restore those levels to normal.
MD Anderson Cancer Center and Exscientia plc formed a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence capabilities of Exscientia in order to advance novel small-molecule oncology therapies.
